Trial Profile
A study evaluating correlation between tumor infiltrating lymphocytes and clinical outcomes in advanced non small cell lung cancer patients treated with Nivolumab.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 11 Oct 2017
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 11 Oct 2017 New trial record
- 12 Sep 2017 Primary end point (correlate TIL density with progression free survival (PFS)) has been met as per the results presented at the 42nd European Society for Medical Oncology Congress
- 12 Sep 2017 Results presented at the 42nd European Society for Medical Oncology Congress